SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03 [Seeking Alpha]
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia [Yahoo! Finance]
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia